Jean Francois Formela, serving as a director at Korro Bio, Inc. (NASDAQ:KRRO), recently completed a series of equity transactions resulting in the disposition of approximately $1,542,970 worth of the company's common stock. The sales were executed in the early days of July 2026, specifically on July 2 and July 6, operating under a pre-arranged Rule 10b5-1 trading plan that Formela initially adopted on April 8, 2026. This structured approach to selling shares is typically designed to facilitate transactions at predetermined times regardless of market conditions, thereby avoiding potential perceptions of trading based on material non-public information.
The timing of these divestments is notable given the recent performance of KRRO shares. The stock has surged 71% over the preceding six months, currently trading at $14.49 and reflecting a market capitalization of $208 million. Despite this upward trajectory, analysis suggests the stock may remain undervalued relative to its fair value estimate. On July 2, indirect holdings associated with Formela disposed of 100,700 shares. This block included 85,955 shares and 14,745 shares, both sold at a weighted average price of $14.03 per share. The actual execution prices for these July 2 transactions ranged from $13.95 to $14.16.
Further sales occurred on July 6, involving 9,323 shares. This second tranche consisted of 817 shares and 8,506 shares, sold at a weighted average price of $13.96 per share. The actual prices for these July 6 transactions ranged from $13.95 to $14.05. The shares sold were held indirectly by Atlas Venture Fund XI, L.P., and Atlas Venture Opportunity Fund II, L.P. Formela serves as a member of the general partners for these funds but explicitly disclaims Section 16 beneficial ownership of the shares, except to the extent of his pecuniary interest. Following these transactions, Atlas Venture Fund XI, L.P. retained 706,556 shares, while Atlas Venture Opportunity Fund II, L.P. held 146,305 shares.
This insider activity coincides with significant developments in Korro Bio's clinical pipeline and analyst coverage. The company recently reported its first-quarter 2026 results, followed by an upgrade from Jones Trading. The firm raised Korro Bio's stock rating from Hold to Buy, establishing a new price target of $23.00. This positive shift in sentiment is attributed to the promising potential of Korro Bio's AATD program. Additionally, Korro Bio plans to present preclinical data at the ASGCT, showcasing a new GalNAc-conjugated RNA editor for alpha-1 antitrypsin deficiency. This new editor demonstrates over 90% editing efficiency in vivo, highlighting the company's technological capabilities.
Korro Bio also announced the addition of KRRO-111 to its pipeline, aimed at treating alpha-1 antitrypsin deficiency. This candidate is designed to repair a pathogenic variant on AAT mRNA, thereby restoring normal protein production. Meanwhile, H.C. Wainwright adjusted its price target for Korro Bio to $15 from $20, although it maintained a Buy rating. The firm noted that Korro Bio's lead program, KRRO-121, remains on track for a regulatory filing in the second half of 2026. These developments underscore the critical nature of clinical milestones and regulatory pathways in shaping valuation scenarios for biotech firms.